Table 4.
Characteristics of specific breast cancer subtypes using BIRADS lexicon.
| LA | LB HER2− | LB HER2+ | HER2+ | TNBC | ||
|---|---|---|---|---|---|---|
| Shape | ||||||
| Oval | 0/33 (0%) |
0/17 (0%) |
0/17 (0%) |
1/16 (6%) |
0/19 (0%) |
|
| Round | 2/33 (6%) |
0/17 (0%) | 0/17 (0%) |
0/16 (0%) |
0/19 (0%) |
|
| Irregular | 31/33 (94%) |
17/17 (100%) |
17/17 (100%) |
15/16 (94%) |
19/19 (100%) |
|
| Orientation | ||||||
| Parallel | 25/33 (76%) |
16/17 (94%) |
16/17 (94%) |
15/16 (94%) |
15/19 (79%) |
|
| Non-parallel | 8/33 (24%) |
1/17 (6%) |
1/17 (6%) |
1/16 (6%) |
4/19 (21%) |
|
| Margin | ||||||
| Circumscribed | 0/33 (0%) |
0/17 (0%) |
0/17 (0%) |
2/16 (12.5%) |
0/19 (0%) |
|
| Not circumscribed | Indistinct | 9/33 (27%) |
4/17 (24%) |
4/17 (24%) |
2/16 (12.5%) |
8/19 (42%) |
| Angular/ spiculated |
21/33 (64%) |
13/17 (76%) |
11/17 (64%) |
10/16 (62.5%) |
9/19 (47%) |
|
| Micro/ macrolobulated |
3/33 (9%) |
0/17 (0%) |
2/17 (12%) |
2/16 (12.5%) |
2/19 (11%) |
|
| Echo pattern | ||||||
| Complex/hypoechoic | 29/33 (88%) |
16/17 (94%) |
16/17 (94%) |
14/16 (87,5%) |
19/19 (100%) | |
| Hyper/isoechoic | 4/33 (12%) |
1/17 (6%) |
1/17 (6%) |
2/16 (12,5) |
0/19 (0%) |
|
| Posterior features | ||||||
| No Posterior Features | 13/33 (39%) |
5/17 (29%) |
3/17 (18%) |
3/16 (19%) |
2/19 (11%) |
|
| Enhancement | 0/33 (0%) |
1/17 (6%) |
3/17 (18%) |
6/16 (37.5%) |
4/19 (21%) |
|
| Shadowing | 7/33 (22%) |
4/17 (23%) |
8/17 (47%) |
2/16 (12.5%) |
5/19 (26%) |
|
| Combined Pattern | 13/33 (39%) | 7/17 (41%) |
3/17 (18%) |
5/16 (31%) |
8/19 (42%) |
|
| Calcifications | ||||||
| Present | 13/33 (39%) |
12/17 (71%) |
13/17 (76.5%) |
12/16 (75%) |
4/19 (21%) |
|
| Absent | 20/33 (61%) |
5/17 (29%) |
4/17 (23.5%) |
4/16 (25%) |
15/19 (79%) |
|
| Additional features | ||||||
| Skin changes | 4/33 (12%) |
6/17 (35%) |
6/17 (35%) |
2/16 (12.5%) |
3/19 (16%) |
|
| Edema | 24/33 (73%) |
10/17 (59%) |
12/17 (71%) |
9/16 (56%) |
14/19 (74%) |
|
| Vascularity | 28/33 (85%) | 17/17 (100%) |
16/17 (94%) |
15/16 (94%) |
18/19 (95%) |
|
| Elastography | ||||||
| Soft | 7/33 (21%) | 1/17 (6%) |
1/17 (6%) |
3/16 (19%) |
2/19 (10%) |
|
| Intermediate | 12/33 (36%) |
5/17 (29%) |
6/17 (35%) |
2/16 (12%) |
10/19 (53%) |
|
| Hard | 14/33 (42%) |
11/17 (65%) |
10/17 (59%) |
11/16 (69%) |
7/19 (37%) |
|
LA = luminal A; LB HER2− = luminal B without HER2 overexpression; LB HER2+ = luminal B with HER2 overexpression; HER2+ = human epidermal growth factor receptor 2 positive; TNBC = triple negative breast cancer.